Details of the Drug

General Information of Drug (ID: DMYGK1D)

Drug Name
OTL-300
Indication
Disease Entry ICD 11 Status REF
Beta thalassemia 3A50.2 Phase 1/2 [1]
Drug Type
Gene therapy
Cross-matching ID
TTD ID
D1RMS5

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hemoglobin subunit beta (HBB) TTM6HK1 HBB_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03275051) Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Orchard Therapeutics.